Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients

BMC Psychiatry

Volumn 11, Issue , 2011, Pages

  Raffa, Monia ^a   Atig, Fatma ^a   Mhalla, Ahmed ^a   Kerkeni, Abdelhamid ^a   Mechri, Anwar ^a  

^a UNIVERSITY OF MONASTIR   (Tunisia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CATALASE; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; SUPEROXIDE DISMUTASE; ANTIOXIDANT; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; OXIDATIVE STRESS; PSYCHOSIS; SCHIZOPHRENIA; SPECTROPHOTOMETRY; BLOOD; CASE CONTROL STUDY; ENZYMOLOGY; METABOLISM; METHODOLOGY; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; STATISTICS;

ADULT; ANTIOXIDANTS; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CATALASE; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SPECTROPHOTOMETRY; SUPEROXIDE DISMUTASE;

EID: 79960889350     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-11-124     Document Type: Article

References (52)

1. Zhang M, Zhao Z, He L, Wan C. Ameta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci 2010, 53:112-124. 10.1007/s11427-010-0013-8, 20596963.
2. Bitanihirwe Byron KY, Woo Tsun-Ung W. Oxidative stress in schizophrenia: An integrated approach. Neuroscience and Biobehavioral 2011, 35:878-893.
3. Mukherjee S, Mahadik SP, Scheffer R, Correnti EE, Kelkar H. Impaired antioxidant defense at the onset of psychosis. Schizophr Res 1996, 19:19-26. 10.1016/0920-9964(95)00048-8, 9147492.
4. Drevet JR. The antioxidant glutathione peroxidase family and spermatozoa: A complex story. MCE. Essent Fatty Acids 2006, 55:45-54.
5. Burton G J, Jauniaux E. Oxidative stress. Best Pract Res Clin Obstet Gynaecol 2010,
6. Mahadik SP, Pillai A, Joshi S, Foster A. Prevention of oxidative stress-mediated neuropathology and improved clinical outcome by adjunctive use of a combination of antioxidants and omega-3 fatty acids in schizophrenia. Int Rev Psychiatry 2006, 18:119-131. 10.1080/09540260600581993, 16777666.
7. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 2002, 20:171-175. 10.1002/cbf.940, 11979513.
8. Zhang XY, Zhou DF, Cao LY, Chen DC, Zhu FY, Wu GY. Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr Res 2003, 62:245-250. 10.1016/S0920-9964(02)00352-3, 12837521.
9. Akyol O, Herken H, Uz E, Fadillioglu E, Unal S, Sogut S, Ozyurt H, Savaş HA. The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:995-1005. 10.1016/S0278-5846(02)00220-8, 12369276.
10. Zhang XY, Tan YL, Cao LY, Wu GY, Xu Q, Shen Y, Zhou DF. Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophr Res 2006, 81:291-300. 10.1016/j.schres.2005.10.011, 16309894.
11. Ben Othmen L, Mechri A, Fendri C, Bost M, Chazot G, Gaha L, Kerkeni A. Altered antioxidant defense system in clinically stable patients with schizophrenia and their unaffected siblings. Prog Neuro-psychopharmacol Biol Psychiatry 2008, 32:155-159.
12. Herken H, Uz E, Ozyurt H, Sogut S, Virit O, Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001, 6:66-73. 10.1038/sj.mp.4000789, 11244487.
13. Yao JK, Reddy R, Mc Elhinny LG, Van Kammen DP. Effects of haloperidol on antioxidant defense system enzymes in schizophrenia. J Psychiatr Res 1998, 32:385-391. 10.1016/S0022-3956(98)00028-4, 9844955.
14. Yao JK, Reddy RD, Van Kammen DP. Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol Psychiatry 1999, 45:1512-1515. 10.1016/S0006-3223(98)00184-X, 10356635.
15. Reddy R, Sahebarao MP, Mukherjee S, Murthy JN. Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol Psychiatry 1991, 30:409-412. 10.1016/0006-3223(91)90298-Z, 1912133.
16. Srivastava N, Barthwal MK, Dalal PK, Agarwal AK, Nag D, Srimal RC, Seth PK, Dikshit M. Nitrite content and antioxidant enzyme levels in the blood of schizophrenia patients. Psychopharmacology (Berl) 2001, 158:140-145.
17. Dakhale G, Khanzode S, Khanzode S, Saoji A, Khobragade L, Turankar A. Oxidative damage and schizophrenia: the potential benefit by atypical antipsychotics. Neuropsychobiology 2004, 49:205-209. 10.1159/000077368, 15154399.
18. Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB, Mahadik SP. Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 2003, 121:109-122. 10.1016/S0165-1781(03)00220-8, 14656446.
19. Carmeli E, Bachar A, Barchad S, Morad M, Merrick J. Antioxidant status in the serum of persons with intellectual disability and hypothyroidism: a pilot study. Res Dev Disabil 2008, 29:431-438. 10.1016/j.ridd.2007.08.001, 17869479.
20. Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins Leukot Essent Fatty Acids 2003, 69:393-399. 10.1016/j.plefa.2003.08.010, 14623492.
21. Pulido R, Jimenez-Escrig A, Orensanz L, Saura-Calixto F, Jimenez-Escrig A. Study of plasma antioxidant status in Alzheimer's disease. Eur J Neurol 2005, 12:531-535. 10.1111/j.1468-1331.2005.01000.x, 15958093.
22. Ustundag B, Atmaca M, Kirtas O, Selek S, Metin K, Tezcan E. Total antioxidant response in patients with schizophrenia. Psychiatry Clin Neurosci 2006, 60:458-464. 10.1111/j.1440-1819.2006.01532.x, 16884448.
23. Wood SJ, Berjer GE, Wellard RM, Proffitt TM, Mc Conchie M, Berk M, et al. Medial tempral lobe glutathione concentration in first episode psychosis: A1H-MRS investigation. Neurobiol Dis 2009, 3:354-357.
24. Do KQ, Trabesinger AH, Kirsten-Kruger M, Lauer CJ, Dydak U, Hell D, Holsboer F, Boesiger P, Cuénod M. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci 2000, 12:3721-3728. 10.1046/j.1460-9568.2000.00229.x, 11029642.
25. Yao JK, Leonard S, Reddy R. Altered glutathione redox state in schizophrenia. Dis Markers 2006, 22:83-93.
26. Pavlovic D, Tamburic V, Stojanovic I, Kocic G, Jevtovic T, Dordevic V. Oxidative stress asmarkers of positive symptoms in schizophrenia. Med Biol 2002, 9:157-161.
27. Altuntas I, Aksoy H, Coskun I, Cayköylü A, Akçay F. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med 2000, 38:1277-1281. 10.1515/CCLM.2000.201, 11205693.
28. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry 2009, 33:1178-1183. 10.1016/j.pnpbp.2009.06.018, 19576938.
29. Saadat M, Mobayen F, Farrashbandi H. Genetic polymorphisms of glutathione S-transferase T1: a candidate genetic modifier of individual susceptibilty to schizophrenia. Psychiatry Res 2007, 153:87-91. 10.1016/j.psychres.2006.03.024, 17586054.
30. Tosic M, Ott J, Barral S, Bovet P, Deppen P, Gheorghita F, et al. Schizophrenia and oxidative stress: glutamate cysteine ligase modifier as a susceptibility gene. Am J Hum Genet 2006, 79:586-592. 10.1086/507566, 1559555, 16909399.
31. American Psychiatric Association DSM-IV-TR. Diagnostic and Statistical Manual of mental disorders 2000, Washington DC: American Psychiatric Press, fourth, American Psychiatric Association.
32. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974, 47:469-474. 10.1111/j.1432-1033.1974.tb03714.x, 4215654.
33. Gunzler WA, Kremers H, Flohe L. An improved coupled test procedure for glutathione peroxidase in blood. Z Klin Biochem 1974, 12:444-448.
34. Beer B, Sizer W. A spectrophotometry method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 1952, 195:133-139.
35. Akerboom TP, Sies DH. Assay of glutathione, glutathione disulfide and glutathione mixed disulfides in biological samples. Methods enzymol detoxification and drug metabolism: conjugation and related systems 1981, 373-382. London: Academic Press, Jakoly W.
36. Andreasen NC. Scale for the Assessment of Negative Symptoms 1983, University of Iowa, Iowa City IA.
37. SPSS.10.0 statistical package for the Social sciences (SPSS) for windows, version 10.0 1994, Chicago.IL: SPSS Inc.
38. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004, 7:684-697.
39. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, Takanashi J, Matsuda T, Shimizu E, Ikehira H, Iyo M, Hashimoto K. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS ONE 2008, 4:e1944.
40. Terpstra M, Vaughan TJ, Ugurbil K, Lim KO, Schulz SC, Gruetter R. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia. MAGMA 2005, 18:276-282. 10.1007/s10334-005-0012-0, 16320094.
41. Mico JA, Rojas-Corrales MO, Gibert-Rahola J, Parellada M, Moreno D, Fraguas D, et al. Reduced antioxidant defense in early onset first-episode psychosis: a case control study. BMC Psychiatry 2011, 11:26. 10.1186/1471-244X-11-26, 3045298, 21320302.
42. Mahadik SP, Mukherjee S, Correnti EE, Scheffer R. Elevated levels of lipid peroxidation production plasma of drug-naive patients at the onset of psychosis. Schizophr Res 1995, 15:66.
43. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr Res 1996, 19:1-17. 10.1016/0920-9964(95)00049-6, 9147491.
44. Ersan S, Bakir S, Erdal Ersan E, Dogan O. Examination of free radical metabolism and antioxidant defense system elements in patients with obsessive-compulsive disorder. Prog neuropsychopharmacol Biol Psychiatry 2006, 6:1039-1042.
45. Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O. Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 2004, 19:89-95. 10.1097/00004850-200403000-00006, 15076017.
46. Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V, Da Silva V, et al. Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 2007, 421:33-36. 10.1016/j.neulet.2007.05.016, 17548157.
47. Baez S, Segura-Aguilar J, Widersten M, Johansson AS, Mannervik B. Glutathione transferases catalyse the detoxication of oxidized metabolites (o-quinones) of catecholamines and may serve as an antioxidant system preventing degenerative cellular processes. Biochem J 1997, 324:25-28. 1218396, 9164836.
48. Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999, 55:659-665. 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C, 10220107.
49. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991, 148:1474-1486.
50. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008, 11:851-876.
51. Gysin R, Kraftsik R, Sandell J, Bovet P, Chappuis C, Conus P, et al. Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc Natl Acad Sci USA 2007, 104:16621-16626. 10.1073/pnas.0706778104, 2034265, 17921251.
52. Younes-Mhenni S, Frih-Ayed M, Kerkeni A, Bost M, Chazot G. Peripheral blood markers of oxidative stress in Parkinson's disease. Eur Neurol 2007, 58:78-83.